Compare Icl Group Ltd (ICL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Novo Nordisk A/S — how do they compare? Icl Group Ltd trades at $5.01 (market cap $6.65B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 33.2× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| ICL | NVO | |
|---|---|---|
Market Cap | $6.65B | $220.53B |
Sector | Basic Materials | Health |
52-Week High | $7.03 | $71.70 |
52-Week Low | $4.80 | $35.29 |
Enterprise Value | $9.22B | $239.49B |
Dividend Yield | 3.77% | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
